In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan

Max Gelman

Senior Editor

Amicus received a healthy heaping of good news last month when analysts threw cold water on Sanofi’s late-onset Pompe disease ERT, after a Phase III …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

In an­tic­i­pa­tion of PhI­II tri­al re­sults, Am­i­cus pares down old debt with $400 mil­lion loan

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan